




December 2010

Volume 15 · Numbers 23/24

pp. 983–1114



Cover Story

The leading story of this issue of Drug Discovery Today, by Sunita J. Shukla, Ruili Huang, Christopher P. Austin and Menghang Xia highlights the US Tox21 collaborative program and how it has brought about a change in approach in toxicity testing of chemical compounds. Standard *in vivo* testing is being superseded to an extent by higher throughput *in vitro* assay techniques. This approach is prioritizing compounds for further mechanism of action studies and the development of models to predict adverse events in humans.

DRUG DISCOVERY TODAY

REVIEWS

FOUNDATION

997 The future of toxicity testing: a focus on *in vitro* methods using a quantitative high-throughput screening platform

Sunita J. Shukla, Ruili Huang, Christopher P. Austin and Menghang Xia

GENE TO SCREEN

1008 Epigenetic therapies for non-oncology indications

Jonathan D. Best and Nessa Carey

1015 Pharmacoproteomics: a chess game on a protein field

Angelo D'Alessandro and Lello Zolla

INFORMATICS

1024 Connecting the dots: role of standardization and technology sharing in biological simulation

Samik Ghosh, Yukiko Matsuoka and Hiroaki Kitano

POST SCREEN

1032 Lyotropic liquid crystal systems in drug delivery

Chenyu Guo, Jun Wang, Fengliang Cao, Robert J. Lee and Guangxi Zhai

1041 Developments towards antiviral therapies against enterovirus 71

Kan X. Wu, Mary M.-L. Ng and Justin J.H. Chu

1052 PubChem as a public resource for drug discovery

Qingliang Li, Tiejun Cheng, Yanli Wang and Stephen H. Bryant

1058 Heparin/heparan sulphate-based drugs

Neha S. Gandhi and Ricardo L. Mancera

1070 Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives

Maribel Navarro, Chiara Gabbiani, Luigi Messori and Dinorah Gambino